Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Recommendation of “Moderate Buy” from Analysts

Akero Therapeutics, Inc. (NASDAQ:AKRO) has earned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $43.20.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a research report on Tuesday, September 17th.

Insider Buying and Selling

In related news, CEO Andrew Cheng sold 108,366 shares of Akero Therapeutics stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $31.73, for a total transaction of $3,438,453.18. Following the sale, the chief executive officer now directly owns 605,417 shares of the company’s stock, valued at $19,209,881.41. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Andrew Cheng sold 108,366 shares of Akero Therapeutics stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $31.73, for a total transaction of $3,438,453.18. Following the sale, the chief executive officer now directly owns 605,417 shares of the company’s stock, valued at $19,209,881.41. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Catriona Yale sold 8,851 shares of Akero Therapeutics stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $27.53, for a total value of $243,668.03. Following the sale, the insider now directly owns 75,931 shares in the company, valued at $2,090,380.43. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 428,397 shares of company stock valued at $12,997,971 over the last three months. 7.94% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Akero Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. boosted its holdings in Akero Therapeutics by 2,366.0% during the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after purchasing an additional 1,183 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Akero Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after purchasing an additional 446 shares in the last quarter. Eastern Bank acquired a new stake in Akero Therapeutics during the third quarter valued at approximately $100,000. Headlands Technologies LLC boosted its holdings in Akero Therapeutics by 253.5% during the first quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock valued at $107,000 after purchasing an additional 3,024 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its stake in shares of Akero Therapeutics by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock valued at $156,000 after acquiring an additional 1,030 shares during the last quarter.

Akero Therapeutics Trading Up 2.2 %

Shares of NASDAQ:AKRO opened at $32.74 on Wednesday. The company has a market cap of $2.27 billion, a P/E ratio of -9.60 and a beta of -0.26. The stock’s 50-day moving average is $28.54 and its 200-day moving average is $24.97. Akero Therapeutics has a 52-week low of $13.39 and a 52-week high of $37.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.09. Equities research analysts predict that Akero Therapeutics will post -3.64 earnings per share for the current year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.